King's Research Portal

DOI:

[10.1111/his.13002](https://doi.org/10.1111/his.13002)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Mehra, V., Pomplun, S., Ireland, R. M., Devereux, S., Yallop, D., Marcus, R., Shah, C., Patten, P., & Kassam, S. (2016). ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib. *Histopathology*, 69(5), 880-882. <https://doi.org/10.1111/his.13002>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Received Date : 25-Apr-2016
Revised Date : 24-May-2016
Accepted Date : 26-May-2016
Article type : Lesson of the month

Title: ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib

Authors: Varun Mehra¹, Sabine Pomplum², Robin Ireland¹, Deborah Yallop¹, Stephen Devereux¹, Robert Marcus¹, Chirag Shah³, Piers Patten¹, Shireen Kassam¹.

Author Affiliations

1. Department of Haematology, King's College Hospital, London, UK
2. Department of Histopathology, University College Hospital, London, UK
3. Department of Histopathology, King's College Hospital, London, UK

Corresponding Author: Dr Shireen Kassam

Department of Haematology

King's College Hospital

Denmark Hill

London, UK

SE5 9RS

Email: shireen.kassam@nhs.net

Tel: 020 3299 5262

Short running title: ALK-positive large B-cell lymphoma

Key words: Lymphoma, brentuximab, crizotinib

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1111/his.13002

This article is protected by copyright. All rights reserved.

This work highlights a rare diagnostic pitfall and reports lack of efficacy of brentuximab and crizotinib in ALK positive large B-cell lymphoma

We report a case of ALK positive large B-cell lymphoma (ALK-LBCL) with strong CD30 expression, initially misdiagnosed as anaplastic large cell lymphoma (ALCL), ALK positive. These two lymphomas differ in response to chemotherapy and prognosis making accurate diagnosis essential.

A 23-year old female presented with a 3-month history of B symptoms and enlarging lymphadenopathy. She subsequently developed abdominal pain and jaundice with a palpable swelling in the right upper abdominal quadrant. Blood tests revealed obstructive liver function tests, a pancytopenia and an elevated LDH. A computed tomography (CT) scan revealed lymph node masses at the level of the porta hepatis and in the retroperitoneum and a positron emission tomography (PET)-CT scan confirmed widespread FDG avid nodal and extra-nodal disease.

A bone marrow (BM) aspirate showed multiple clusters of large mononuclear cells with abundant basophilic, vacuolated cytoplasm. (Fig 1A, B). The BM trephine showed infiltration by sheets of large atypical cells with prominent nucleoli. These cells were diffusely positive for ALK (cytoplasmic and perinuclear) and CD30, but negative for B-cell, T-cell and myeloid markers (Fig 2 A-C). Fluorescence in situ hybridisation on the BM aspirate using a break-apart probe demonstrated a rearrangement of the *ALK* gene (Fig 1C). The lymph node biopsy showed replacement by sheets of large atypical cells with irregular nuclei and multiple nucleoli. Immunohistochemistry demonstrated strong positive staining for CD30 (cytoplasmic), ALK (cytoplasmic and paranuclear), CD45 and EMA (epithelial membrane antigen) as

well as Bcl-6, CD10 and CD15. Ki67 was 95%. The cells did not express pan B-cell or T-cell markers. Thus, a diagnosis of anaplastic large cell lymphoma, ALK positive with a 'null phenotype' was made.

The patient was treated using the paediatric ALCL 99 protocol¹, following the algorithm for high-risk disease. Following 2 cycles of chemotherapy the patient had progressive disease. Given the CD30 expression, a trial of brentuximab vedotin (BV) was commenced. Although there was a transient response with a fall in LDH levels, after 2 cycles the disease progressed (Fig 1D). A single course of gemcitabine and oxaliplatin chemotherapy was tried without effect. The presence of an *ALK* translocation prompted a two-week trial of crizotinib, an ALK inhibitor, through a company access program. There was an initial fall in LDH levels (Fig 1D) but the patient rapidly deteriorated with circulating tumor cells and died 4 months following initial diagnosis.

Given the unexpected treatment refractory nature of the disease, a review of the diagnostic biopsy was undertaken. Further immunohistochemical stains on the BM trephine showed positivity for CD138 and lambda light chain restriction confirming the B-cell origin of the tumour, more in keeping with ALK-LBCL (Fig 2D, E).

ALK-LBCL is a rare variant of diffuse large B-cell lymphoma (DLBCL), first described in 1997². Since then, fewer than 100 cases have been described. The lymphoma has a bimodal age distribution with primarily nodal involvement and displays an aggressive behavior resulting in a median survival of 12 months³. ALK-LBCL is characterised by the presence of immunoblastic or plasmablastic cells with strong ALK protein expression that is frequently associated with t(2;17)(p23;q23) and more rarely the t(2;5)(p23;q35). Immunohistochemistry

reveals a distinct profile, including a lack of B- and T-cell markers, but expression of CD138 and CD38 and usually cytoplasmic IgA with light chain restriction. CD30 expression is rare, usually focal and weak, with one case series reporting positivity in 11% of cases³.

BV is an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E..Variable CD30 expression has been demonstrated, in DLBCL. A study of BV in relapsed/refractory CD30 positive DLBCL reported a response rate of 44%⁴. There are no data reporting the use of BV in ALK-LBCL.

There are limited experimental and clinical data to suggest that ALK inhibitors may be efficacious in ALK-LBCL. Crizotinib, the small molecule dual inhibitor of the MET and ALK receptor tyrosine kinases, has been reported to produce short-term clinical response^{5, 6}.

This case highlights that the diagnosis of ALK-LBCL can pose a challenge, especially when it is CD30 positive. It also demonstrates the chemorefractory nature of the disease and the dismal prognosis. However, there is hope that a targeted therapy combined with chemotherapy may improve prognosis in the future.

Acknowledgments:

1. VM collected clinical history, investigation results, obtained morphology pictures and wrote the initial manuscript.
2. RI and CS reviewed the pictures
3. SD, RM, PP and DY were involved in the care of the patient
3. SK and SP edited the manuscript for final submission

References

1. Le Deley MC, Rosolen A, Williams DM *et al.* Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized alcl99-vinblastine trial. *J Clin Oncol* 2010;**28**;3987-3993.
2. Delsol G, Lamant L, Mariame B *et al.* A new subtype of large b-cell lymphoma expressing the alk kinase and lacking the 2; 5 translocation. *Blood* 1997;**89**;1483-1490.
3. Beltran B, Castillo J, Salas R *et al.* Alk-positive diffuse large b-cell lymphoma: Report of four cases and review of the literature. *J Hematol Oncol* 2009;**2**;11.
4. Jacobsen ED, Sharman JP, Oki Y *et al.* Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory dlbl with variable cd30 expression. *Blood* 2015;**125**;1394-1402.
5. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. *N Engl J Med* 2011;**364**;775-776.
6. Wass M, Behlendorf T, Schadlich B *et al.* Crizotinib in refractory ALK-positive diffuse large b-cell lymphoma: A case report with a short-term response. *Eur J Haematol* 2014;**92**;268-270.

Figure Legends :

Figure 1

- a) BM aspirate (MGG stain) shows clusters of large atypical pleomorphic mononuclear cells with vacuolated basophilic cytoplasm and eccentric immature nuclei-immunoblastic morphology.
- b) BM aspirate with hypercellular particles and trails with some clustering of tumour cells.
- c) FISH on BM aspirate: Break-apart probe confirming ALK gene rearrangement (separate red & green signal).
- d) Trends in LDH as a bio-marker correlating with disease activity. Note transient decline in LDH when treated with novel agents, suggestive of some response.

Figure 2: BM Trepine:

- a) H&E section (x 40 magnification).
- b) ALK stain positive.
- c) CD30 stain positive.
- d) CD138 stain positive.
- e) Surface lambda Light chain positive.